PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma

Current therapy is ineffective for relapsed and metastatic Ewing sarcoma (EwS) owing to development of drug resistance. Macromolecular prodrugs potentially lead to lower drug exposure in normal tissues and reduced toxicity. We evaluated the efficacy of PEGylated talazoparib (PEG∼TLZ), a PARP1 inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Pozo, Vanessa, Robles, Andrew J., Fontaine, Shaun D., Liu, Qianqian, Michalek, Joel E., Houghton, Peter J., Kurmasheva, Raushan T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783091/
https://www.ncbi.nlm.nih.gov/pubmed/35098099
http://dx.doi.org/10.1016/j.isci.2021.103725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783091/
https://www.ncbi.nlm.nih.gov/pubmed/35098099
http://dx.doi.org/10.1016/j.isci.2021.103725

Ejemplares similares